Summary We could determine the S-phase fraction (SPF) by flow cytometric DNA analysis of paraffin archival material in 160 of 260 patients with soft-tissue sarcoma of extremity and trunk wall. The prognostic value of SPF was compared with other clinicopathological factors. The median follow-up time was 16 Keywords: soft-tissue sarcoma; DNA flow cytometry; S-phase fraction; multivariate analysis; prognosis
The prognostic value of cell proliferative activity has been investigated in soft-tissue sarcoma using several methods. Proliferating cell nuclear antigen (PCNA) and Ki-67 have been associated with poor prognosis (Ueda et al, 1989; Stenfert Kroese et al, 1990 ; Oda et al, 1993; Choong et al, 1994; Dreinhofer et al, 1994; Drobnjak et al, 1994) , whereas others have failed to show this (Herzberg et al, 1992) . Moreover, a high fraction of cells in S-or S+G2-phase, as determined by flow cytometry, has been shown to be prognostic (Becker et al, 1991; Alho et al, 1993) and has also been used to identify patients with short-term response to chemotherapy (Schmidt et al, 1993) . In the present work, we have assessed DNA ploidy status in 260 patients with soft-tissue sarcoma of extremity and trunk wall. In 160 of these tumours, the S-phase fraction (SPF) could be calculated, and its prognostic value was analysed in relation to other clinicopathological factors.
MATERIALS AND METHODS Patients
The population-based database at the Musculoskeletal Tumor Center in Lund, Sweden, holds records of 508 patients with softtissue sarcoma of extremity and trunk wall diagnosed between 1964 and 1989. Patients have been identified via the the Regional Tumor Registry. The database therefore comprises all patients in the Southern Swedish Health Care Region (1.5 million inhabitants), irrespective of whether the patients have been treated at our institution or at local hospitals in the region. Criteria for inclusion, as well as classification of treatment, histopathology, including microscopic tumour necrosis, vascular invasion and malignancy grading, have been described elsewhere (Gustafson 1994a) .
In 260 of these 508 patients, flow cytometric DNA analysis has been performed hitherto on paraffin-embedded material. SPF could be calculated in 160 of these 260 patients. The 160 patients had a median age of 62 (range 18-87) years, and a median tumour size of 7 (range 1-30) cm. One patient had lymph node metastasis at diagnosis. Malignant fibrous histiocytoma (MFH) was the commonest histotype, and grade IV (four-grade scale) the commonest malignancy grade (Table 1 ). All patients were operated on: 55 patients had inadequate local treatment (surgery with an intralesional margin with or without radiotherapy or surgery with a marginal margin without radiotherapy; 21 at the centre and 34 at non-centre hospitals), and 105 patients had adequate local treatment (surgery with a marginal margin with radiotherapy or surgery with a wide or radical margin with or without radiotherapy; 93 at the centre and 12 at non-centre hospitals). Fourteen patients received chemotherapy, two of these preoperatively. These patients were not analysed separately, since they did not differ from those who did not receive chemotherapy as regards clinicopathological factors or outcome.
Forty-six patients developed local recurrence, 27 of the 46 treated outside the centre and 19 of the 114 treated at the centre. At latest follow-up, 58 patients had developed (distant) metastasis, giving a 5-year metastasis-free survival rate (MFSR) of 0.66. The median follow-up time for the 70 patients alive at last follow-up was 16 (range 6-31) years.
Compared with the population-based database, the 160 patients were a representative subset as regards age, sex, tumour localization, tumour depth, tumour size, microscopic tumour necrosis, vascular invasion, local treatment, metastasis rate and length of follow-up. In the present series, tumours of malignancy grades I and II were more common (28% vs 20% in the database), as were Ortho 50 H cytofluorograph (Baldetorp et al, 1989) .
Ploidy status
The DNA histograms were classified into eight types depending on the number of peaks and the pattern of the diploid G/G, peak. (Gustafson, 1994a) . The histograms were grouped into types 1-2 vs types 3-8, which we have shown gives the best prognostic separation (Gustafson, 1994b) .
S-phase fraction S-phase fraction (SPF) was calculated with a planimetric method (Baisch et al, 1975) , assuming the S-phase compartment to constitute a rectangular distribution between the modal values of the GO/G, and G2 peaks, and was expressed as the percentage of nuclei in the S-phase of the total number of nuclei. In case of bimodality in the 2C region, i.e. near-diploidy with a DNA index (DI) for the non-diploid stemline below approximately 1.3, a mean SPF value for the diploid and non-diploid stemline was calculated. When the DI exceeded 1.3 and if the corresponding G2 peaks were distinctly separated, the SPF was calculated exclusively for the non-diploid stemline. In case of two or more non-diploid peaks, the SPF was calculated in the most prominent non-diploid stemline. SPF was not calculated if the corresponding G2 peak in the histogram could not be identified, or if the non-diploid stemline was small (G01GI <15% of the total number of observations), or if the CV exceeded 8%, or if the contribution of debris in the SPF compartment of the histogram was too extensive. Nuclear aggregates were gated out using thresholding capabilities of the DNA analysis software in the Ortho 2140 data handling system. SPF could be calculated in 55 of the 61 type 1 histograms, in 18 of 20 type 2 histograms, in five of six type 3 histograms, in two of two type 4 histograms, in four of eight type 5 histograms, in 45 of 99 type 6 histograms, in 16 of 17 type 7 histograms and in 15 of 47 type 8 histograms. This comprised the 160 patients eligible for analysis. The 100 patients in whom SPF could not be calculated more often had tumours that were MFH or leiomyosarcoma, more often of malignancy grade IV, and more often had vascular invasion, but there were no differences as regards age, sex, localization, depth, tumour size or microscopic tumour necrosis (Table 2 ). These 100 patients had a 5-year MFSR of 0.58 (P = 0.1 in comparison with 5-year MFSR of 0.66 in the 160 patients).
Statistics
The data were analysed using the Mann-Whitney U-test and the chi-square test with the Yates' continuity correction when indicated. Analyses of (distant) metastasis-free survival rates (MFSR) were univariately performed with Kaplan-Meier methods and the generalized Wilcoxon test. A Cox multivariate analysis of prognostic factors for metastasis was performed, and the Wald statistic Figure 1 Metastasis-free survival in 160 patients with soft-tissue sarcoma of extremity and trunk wall using S-phase fraction (SPF). P<0.0001 British Journal of Cancer (1997) 75(1) 
RESULTS

S-phase fraction
The median SPF value for the 160 patients was 6.0% (range 0.1-25%). We had no reason to assume that a specific SPF value would be optimal for prognostic dichotomization, and therefore analysed different cut-off values. We found the best cut-off at 3.0%, which identified 47 patients with SPF <3.0% (= low SPF) and 113 patients with SPF >3.0% (= high SPF). The 5-year MFSRs were 0.94 and 0.53 respectively (P <0.0001) (Figure 1) .
Forty-three of the 47 patients with tumours with low SPF and 53 of the 113 patients with tumours with high SPF had histograms of types 1, 2, 3, 4 or 7. Among these five types, SPF could be calculated in 96 of 106 patients.
Correlation between SPF and other prognostic factors
The 47 patients with low SPF were younger, more often had tumours of low malignancy grade, which were more often DNA diploid, and were without microscopic tumour necrosis or vascular invasion. They also less often had a leiomyosarcoma (Table 3) .
Apart from a better prognosis, patients with low SPF also had a prolonged clinical course; four of the seven patients who developed metastases did so after more than 5 years, compared with 2 of 51 in the patients with high SPF (P <0.0001) (Figure 1 ). The median time to local recurrence was 27 months in the low-SPF group, compared with 6 months in the high-SPF group (P <0.002). These differences could not be explained by different in 78 patients with high SPF (P = 0.0003) (Figure 2) . Among the 41 patients with two or three risk factors, eight patients with low SPF had a 5-year MFSR of 0.75, compared with 0.26 in 33 0 3 6 9 12 15 patients with high SPF, but this difference diminished over time and was not statistically significant (P = 0.1) (Figure 2 ). Among Years the 38 patients with low SPF, 10 tumours were of malignancy grade III (Table 4 ). Highrisk/high SPF (n=33). P-value for lowrisk group = 0.0003. P-value for highrisk group = 0.1 DISCUSSION S-phase fraction (SPF) has been identified as a prognostic factor in several malignancies, breast cancer, non-small-cell lung cancer, colorectal cancer and carcinoma of the ovary (for review, see Merkel and McGuire, 1990) . In soft-tissue sarcoma, several markers of proliferation have yielded prognostic information (Ueda et al, 1989; Stenfert Kroese et al, 1990; Becker et al, 1991; Alho et al, 1993; Oda et al, 1993; Choong et al, 1994; Dreinhofer et al, 1994; Drobnjak et al, 1994) , but SPF has not been thoroughly tested together with other strong clinicopathological factors in a multivariate analysis. In 100 of 260 samples, SPF could not be calculated, a fact that restricts the usefulness of the method. These 100 patients had a different distribution of histotypes and malignancy grades and a worse 5-year MFSR, implying that these 100 patients may belong to a different subset of soft-tissue sarcoma patients. The reasons for the failures in calculation were primarily: (1) the histogram showed a high background distribution; (2) the non-diploid peak represented less than 15% of the observations in the histogram; and (3) the coefficient of variation (CV) was over 8%. If one of these criteria is fulfilled, SPF should, according to international consensus guidelines, not be calculated (Shankey et al, 1993) . In the 100 patients in whom calculation of SPF failed, these phenomena were more often seen, and they may reflect a more malignant tumour. The number of failures may be reduced if fresh tumour tissue is examined, since paraffin-embedded tissue normally, owing to preparation artefacts, gives a higher background contribution than does fresh tissue (Hedley, 1989) . By using fresh material instead of paraffin material, we have in recent years been able to reduce the failure rate to less than 30%, and we are now investigating whether other algorithms for calculation of SPF can reduce this rate further.
Our cut-off value of 3% for low-and high-SPF value was arrived at after an a posteriori analysis. There is no consensus on the cut-off value of SPF in soft-tissue sarcoma using paraffin archival material. Our cut-off, proposed in this exploratory work, has to be tested in other series.
In a univariate analysis, several factors were associated with metastasis, among them microscopic tumour necrosis and high SPF, which were the sole factors that retained their prognostic value in a multivariate analysis. Two other series (Alho et al, 1993; Huuhtanen et al, 1995) have shown a prognostic value of SPF in soft-tissue sarcoma, but none of the series have used multivariate analysis. When combined with our earlier proposed prognostication system using tumour size . 11 cm, microscopic tumour necrosis and vascular invasion (Gustafson, 1994a) , SPF could identify a group as large as one-quarter (38 of 157) of all patients with virtually benign soft-tissue sarcomas; the MFSR was 0.97 after more than 10 years of follow-up. This group contained no patients with tumours of malignancy grade IV, but ten patients had a grade III tumour, which shows the difficulties in correctly predicting prognosis using conventional histological malignancy grading. Furthermore, 43 of 47 patients with low SPF had tumours with histogram types 1, 2, 3, 4 and 7, and in these histogram types SPF could be calculated nine times of ten. Patients with two or three risk factors and also a high SPF had a poor prognosis, and may be suitable candidates for trials with adjuvant therapy. In patients with tumours with low SPF, four of seven metastases were detected after more than 5 years of follow-up. Also, the median time to local recurrence was longer in this group. This should be contrasted with our large population-based series, in which around 90% of metastases and local recurrences were detected within 3 years after diagnosis of the primary tumour (Gustafson, 1994a) . This finding is of clinical importance; low SPF may identify a group of patients who may be at risk of developing metastasis and/or local recurrence for a longer time period, and may require a longer follow-up period.
We conclude that SPF as determined by FCM is, together with microscopic tumour necrosis, an independent prognostic factor for metastasis in soft-tissue sarcoma. The high overall failure rate (40%) must be noted, but since this rate was only 10% in the group in which the prognostic influence was strongest, it should not limit the usefulness. It may, in combination with our earlier prognostication system, identify patients with a very good prognosis. Furthermore, it may be used to identify patients who require a longer follow-up.
